Close for now Do you hold SG, US, HK or MY stocks? How are you tracking them now?
View our Demo portfolio to learn how StocksCafe will do it for you intelligently!
Sign up for free now!

USX:BAX - Baxter International Inc. (USD 67)
Baxter International Inc.

Add to WatchList

Set Alert


USD 67.0    +0.810 (+1.22%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

12 Dec 2018


Overview

12 Dec 2018

Day Change: 0.810 (1.22%)

52 Wk Range: 61.05 - 78.38

Day's Range: 66.94 - 67.745

Last Volume: 3,159,428

Current Yield: 1.09%

Open: USD 66.97

Close: USD 67.0

12 Dec 2018

Metric BAX S.Median
Beta 0.91 0.77
VaR 14.15 20.47
E.Shortfall 19.98 28.44
Liquidity 3.28M 102.03K

Fundamental

12 Dec 2018

PE: 30.359

Market Cap: 36.6B

Price Over Book: 4.007

Price Over Sales: 3.31

Return On Assets: 7.2%

Return On Equity: 13.2%

NAV Over Price: [Friends Only]

Screener

[Members Only]

Sign up for free to access most features of StocksCafe

Scorer

[Members Only]

Sign up for free to access most features of StocksCafe

Description

Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. It offers its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. The company has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. It also has a strategic partnership with ScinoPharm Taiwan, Ltd. to develop, manufacture, and commercialize five injectable drugs for cancer treatments, such as lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, and side effects of chemotherapy. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

General

CEO: Joe Almeida

Headquarters: Deerfield

Employees: 48,000

Sector: Distribution Services

Industry: Medical Distributors

Useful Links
Homepage

Price Simulation

My Notes

You currently do not have notes about this stock.




Past Transactions Add Transactions

You do not have past transactions for this stock.


Shared Portfolios Stats
All Shared Portfolios
0% holds BAX (0/181)
0% recent buy involves BAX (0/98)
0% recent sell involves BAX (0/43)

*recent means in the last 14 days.


Similar Stocks ReShape Lifesciences Inc

Daxor Corp.

Owens & Minor, Inc.

ENDRA Life Sciences Inc

Tandem Diabetes Care Inc